V

Valkyrie Clinical Trials | Los Angeles, CA

Research site
(Unclaimed)
Location
2080 Century Park E #803, Los Angeles, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

36 of 42
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously a...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how...

Enrolling
Advanced Solid Tumors
Drug: WGI-0301

This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has...

Enrolling
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Drug: BI 765049
Drug: ezabenlimab

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Capecitabine

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or w...

Active, not recruiting
Advanced Solid Tumors
Drug: Adagrasib
Drug: BMS-986466

This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other place...

Enrolling
Ovarian Neoplasms
Carcinoma, Non-Small-Cell Lung
Drug: disitamab vedotin

The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify...

Enrolling
Advanced Solid Tumors
Drug: adagrasib
Drug: INCB099280

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Enrolling
Non-small Cell Lung Cancer
NSCLC
Drug: Placebo
Drug: Tislelizumab

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without...

Enrolling
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Paclitaxel
Drug: Nab paclitaxel

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Endometrial Cancer
Biological: vudalimab

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with r...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Zanubrutinib

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Enrolling
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for who...

Enrolling
Neoplasm Metastasis
Non-Small Cell Lung Cancer
Drug: zongertinib

This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment...

Enrolling
Solid Tumors
Drug: Ezabenlimab
Drug: BI 1703880

This study is open to adults with head and neck cancer or liver cancer. This is a study for people for whom previous treatment was not successful or...

Active, not recruiting
Head and Neck Squamous Cell Carcinoma (HNSCC)
Drug: Cetuximab
Other: Investigator´s Choice Chemotherapy

This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemothera...

Enrolling
Non-Small Cell Lung Cancer
Biological: Pembrolizumab Injection
Biological: Ivonescimab Injection

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined w...

Active, not recruiting
PTEN Loss of Function Mutation
PIK3CA Mutation
Drug: Nab paclitaxel
Drug: Serabelisib

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previ...

Enrolling
Small Cell Lung Carcinoma
Neuroendocrine Neoplasms
Drug: BI 764532, formulation 2
Drug: BI 764532, formulation 1

Trial conditions

Non-Small-Cell Lung Carc... (13 trials)
Cancer (12 trials)
Carcinoma (11 trials)
Lung Cancer (8 trials)
Squamous Cell Carcinoma... (5 trials)
Colorectal Cancer (4 trials)
Squamous Cell Carcinoma (4 trials)
Adenocarcinoma (3 trials)
Neoplasm Metastasis (3 trials)
Renal Cell Carcinoma (3 trials)

And 37 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems